Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study

Fortunato Morabito; Giovanni Tripepi; Giovanni Del Poeta; Francesca Romana Mauro; Gianluigi Reda; Paolo Sportoletti; Luca Laurenti; Marta Coscia; Yair Herishanu; Marzia Varettoni; Roberta Murru; Annalisa Chiarenza; Andrea Visentin; Adalgisa Condoluci; Riccardo Moia; Daniela Pietrasanta; Giacomo Loseto; Ugo Consoli; Ilaria Scortechini; Francesca Maria Rossi; Antonella Zucchetto; Ernesto Vigna; Enrica Antonia Martino; Francesco Mendicino; Cirino Botta; Daniele Caracciolo; Ramona Cassin; Graziella D'Arrigo; Sara Galimberti; Angela Rago; Ilaria Angeletti; Annalisa Biagi; Ilaria Del Giudice; Riccardo Bomben; Antonino Neri; Gilberto Fronza; Giovanna Cutrona; Davide Rossi; Francesco Di Raimondo; Antonio Cuneo; Gianluca Gaidano; Aaron Polliack; Livio Trentin; Robin Foà; Manlio Ferrarini; Valter Gattei; Massimo Gentile

doi:10.1002/ajh.26127

Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study

Am J Hematol. 2021 May 1;96(5):E168-E171. doi: 10.1002/ajh.26127. Epub 2021 Feb 24.

Authors

Fortunato Morabito^{1

2}, Giovanni Tripepi³, Giovanni Del Poeta⁴, Francesca Romana Mauro⁵, Gianluigi Reda⁶, Paolo Sportoletti⁷, Luca Laurenti⁸, Marta Coscia⁹, Yair Herishanu¹⁰, Marzia Varettoni¹¹, Roberta Murru¹², Annalisa Chiarenza¹³, Andrea Visentin¹⁴, Adalgisa Condoluci¹⁵, Riccardo Moia¹⁶, Daniela Pietrasanta¹⁷, Giacomo Loseto¹⁸, Ugo Consoli¹⁹, Ilaria Scortechini²⁰, Francesca Maria Rossi²¹, Antonella Zucchetto²¹, Ernesto Vigna^{1

22}, Enrica Antonia Martino²², Francesco Mendicino²², Cirino Botta²², Daniele Caracciolo²², Ramona Cassin⁶, Graziella D'Arrigo³, Sara Galimberti²³, Angela Rago²⁴, Ilaria Angeletti²⁵, Annalisa Biagi⁴, Ilaria Del Giudice⁵, Riccardo Bomben²¹, Antonino Neri⁶, Gilberto Fronza²⁶, Giovanna Cutrona²⁷, Davide Rossi¹⁵, Francesco Di Raimondo¹³, Antonio Cuneo²⁸, Gianluca Gaidano¹⁶, Aaron Polliack²⁹, Livio Trentin¹⁴, Robin Foà⁵, Manlio Ferrarini³⁰, Valter Gattei²¹, Massimo Gentile^{1

22}

Affiliations

¹ Department of Onco-Hematology, Biotechnology Research Unit, AO of Cosenza, Cosenza, Italy.
² Hematology and Bone Marrow Transplant Unit, Hemato-Oncology Department, Augusta Victoria Hospital, East Jerusalem, Israel.
³ Department of Medicine, CNR-IFC, Research Unit of Reggio Calabria, Reggio Calabria, Italy.
⁴ Division of Hematology, S. Eugenio Hospital and University of Tor Vergata, Rome, Italy.
⁵ Hematology, Department of Translational and Precision Medicine, 'Sapienza' University, Rome, Italy.
⁶ Department of Onco-Hematology, Ematologia, Fondazione IRCCS Ca'Granda Ospedale Maggiore Policlinico di Milano, Milano, Italy.
⁷ Centro di Ricerca Emato-Oncologica (CREO), University of Perugia, Perugia, Italy.
⁸ Department of Onco-Hematology, Fondazione Universitaria Policlinico A Gemelli di Roma, Roma, Italy.
⁹ Division of Hematology, A.O.U. Città della Salute e della Scienza di Torino, Torino, Italy.
¹⁰ Sourasky Medical Center, Institute of Hematology, and Sackler Faculty of Medicine, Tel-Aviv University Tel-Aviv, Israel.
¹¹ Division of Haematology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
¹² Hematology and Stem Cell Transplantation Unit, Ospedale A. Businco, Cagliari, Italy.
¹³ Division of Hematology, Policlinico, Department of Surgery and Medical Specialties, University of Catania, Italy.
¹⁴ Department of Medicine, Hematology and Clinical Immunology Branch, University of Padova, Padova, Italy.
¹⁵ Department of Onco-Hematology, Hematology, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland.
¹⁶ Division of Hematology, Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy.
¹⁷ Division of Hematology, Azienda Ospedaliera SS Arrigo e Biagio e Cesare Arrigo, Alessandria, Italy.
¹⁸ Hematology and Cell Therapy Unit, IRCCS-Istituto Tumori 'Giovanni Paolo II', Bari, Italy.
¹⁹ Department of Onco-Hematology, Hematology Department, G. Garibaldi Hospital, Catania, Italy.
²⁰ Department of Onco-Hematology, Clinica di Ematologia Ospedali Riuniti, Ancona, Italy.
²¹ Clinical and Experimental Onco-Hematology Unit, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano, Italy.
²² Department of Onco-Hematology, Hematology Unit AO of Cosenza, Cosenza, Italy.
²³ Section of Hematology, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
²⁴ Department of Onco-Hematology, UOSD Ematologia ASL Roma 1, Roma, Italy.
²⁵ Department of Onco-Hematology, Reparto di Oncoematologia Azienda Ospedaliera Santa Maria di Terni, Terni, Italy.
²⁶ Mutagenesis and Cancer Prevention Unit, IRCCS Ospedale Policlinico San Martino, Genoa, Italy.
²⁷ Molecular Pathology Unit, IRCCS Ospedale Policlinico San Martino, Genova, Italy.
²⁸ Hematology Section, Department of Medical Sciences, University of Ferrara, Ferrara, Italy.
²⁹ Department of Hematology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.
³⁰ Department of Experimental Medicine, University of Genoa, Genoa, Italy.

PMID: 33580969
DOI: 10.1002/ajh.26127

No abstract available

Publication types

Letter
Validation Study

MeSH terms

Adenine / analogs & derivatives*
Adenine / therapeutic use
Aged
Antineoplastic Agents / therapeutic use*
Datasets as Topic / statistics & numerical data
Female
Follow-Up Studies
Humans
Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy*
Leukemia, Lymphocytic, Chronic, B-Cell / mortality
Male
Middle Aged
Multicenter Studies as Topic
Piperidines / therapeutic use*
Prognosis
Progression-Free Survival
Proportional Hazards Models
Protein Kinase Inhibitors / therapeutic use*
Reproducibility of Results
Retrospective Studies
Risk Assessment
Severity of Illness Index*
Survival Analysis

Substances

Antineoplastic Agents
Piperidines
Protein Kinase Inhibitors
ibrutinib
Adenine